Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20094 Phase 1 Study in Healthy Subjects
NCT05116410Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2021
- Primary completion
- Oct 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olatorepatide in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Incidence of adverse events at Day 50. Status: unknown.
02
Drugs
olatorepatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05116410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116410.